MGMT genomic rearrangements contribute to chemotherapy resistance in gliomas

Temozolomide (TMZ) is an oral alkylating agent used for the treatment of glioblastoma and is now becoming a chemotherapeutic option in patients diagnosed with high-risk low-grade gliomas. The O-6-methylguanine-DNA methyltransferase (MGMT) is responsible for the direct repair of the main TMZ-induced...

Descripción completa

Detalles Bibliográficos
Autores principales: Oldrini, Barbara, Vaquero-Siguero, Nuria, Mu, Quanhua, Kroon, Paula, Zhang, Ying, Galán-Ganga, Marcos, Bao, Zhaoshi, Wang, Zheng, Liu, Hanjie, Sa, Jason K., Zhao, Junfei, Kim, Hoon, Rodriguez-Perales, Sandra, Nam, Do-Hyun, Verhaak, Roel G. W., Rabadan, Raul, Jiang, Tao, Wang, Jiguang, Squatrito, Massimo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7403430/
https://www.ncbi.nlm.nih.gov/pubmed/32753598
http://dx.doi.org/10.1038/s41467-020-17717-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7403430/
https://www.ncbi.nlm.nih.gov/pubmed/32753598
http://dx.doi.org/10.1038/s41467-020-17717-0

Ejemplares similares